

23 October 2020

Dear Shareholder

**Bio-Gene Technology Limited (ASX:BGT)
2020 Annual General Meeting of Shareholders (2020 AGM)**

Bio-Gene Technology Limited (**Company**) will hold its 2020 AGM at 11.00am (AEDT) on Thursday, 26 November 2020.

Due to the COVID-19 pandemic and based on the best information available to the Board at the time of preparation of the notice of the meeting, the 2020 AGM will be held as a virtual meeting via Zoom. Shareholders wishing to attend the 2020 AGM are strongly encouraged to participate online and register at least two business days before the virtual meeting by following this link:

https://us02web.zoom.us/webinar/register/WN_wjlkOqsSpuiVO2e9kRlyw

After registering, shareholders will receive a confirmation containing information on how to attend the virtual meeting on the day of the AGM.

Shareholders are also strongly encouraged to lodge their completed proxy forms in accordance with the instructions in the Notice of the 2020 AGM.

Temporary modifications to the *Corporations Act 2001* (Cth) allow the Notice of the 2020 AGM to be made available electronically. The Notice of Meeting can be accessed on the Company's website at <http://bio-gene.com.au/investors/asx-announcements/> and via the ASX Market Announcements Platform under the Company's ASX Code (BGT).

If you have nominated an email address and elected to receive electronic communications from the Company's share registry, Automic Registries, you will receive an email with a link to an electronic copy of the Notice of Meeting.

The business of the 2020 AGM is important to all Shareholders and therefore it is important that Shareholders vote. Lodging a completed proxy is the simplest way to vote at the AGM.

Voting virtually at the Meeting

Shareholders who wish to vote virtually on the day of the AGM will need to login to the Automic website (<https://investor.automic.com.au/#/home>) with their username and password.

Shareholders who do not have an account with Automic are strongly encouraged to register for an account as soon as possible and well in advance of the Meeting to avoid any delays on the day of the Meeting.

How do I create an account with Automic?

To create an account with Automic, please go to the Automic website (<https://investor.automic.com.au/#/home>), click on 'register' and follow the steps. Shareholders will require their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) to create an account with Automic.

I have an account with Automic, what are the next steps?

Shareholders who have an existing account with Automic (Note: with a username and password) are advised to take the following steps to attend and vote virtually on the day of the AGM:

- 1 Login to the Automic website (<https://investor.automic.com.au/#/home>) using your username and password.
- 2 **(Registration on the day)** If registration for the virtual meeting is open, click on 'Meeting open for registration' and follow the steps.
- 3 **(Live voting on the day)** If live voting for the virtual meeting is open, click on 'Meeting open for voting' and follow the steps.

If it becomes necessary or appropriate to make alternative arrangements for the holding or conducting of the 2020 AGM, the Company will make further information available through the ASX Market Announcements Platform and on its website.

Yours faithfully



Roger McPherson
Company Secretary

Bio-Gen Technology Limited

ACN 071 735 950

Notice of 2020 Annual General Meeting

To be held virtually on
Thursday, 26 November 2020 at 11am (Melbourne time)

Due to the ongoing impacts of COVID-19, the Annual General Meeting (AGM) will be held via a live webinar. If you are a shareholder who wishes to attend and participate in the virtual meeting, please register in advance at

https://us02web.zoom.us/webinar/register/WN_wjlqkOqsSpuiVO2e9kRlyw

at least two business days before the meeting. After registering, you will receive a confirmation containing information on how to attend the virtual meeting on the day of the AGM. Arrangements will be made for direct voting at the virtual meeting by shareholders, proxies, corporate representatives and holders of powers of attorney.

Shareholders will be able to ask questions at the virtual meeting. Alternatively, the Company is happy to accept and answer questions submitted at least two business days prior to the meeting by email to bgt.shareholder@bio-gene.com.au. The Company reserves the right to not respond to any unreasonable and/or offensive questions at its discretion.

Shareholders are strongly encouraged to lodge their completed proxy forms appointing the Chair as early as possible and in any event prior to the cut-off for proxy voting as set out in the Notice (being Tuesday, 24 November 2020 at 11am). Instructions for lodging proxies are included on your personalised proxy form.

Because the conditions and potential restrictions and other requirements for meetings relating to COVID-19 are rapidly changing, if it becomes necessary or appropriate to make alternative arrangements to those set out in this Notice the Company will announce the alternative arrangements to ASX. Shareholders are encouraged to check for announcements at the ASX website www.asx.com.au, search code "BGT".

Following recent modifications brought to the Corporations Act 2001 and the Corporations Regulations 2001 under the Corporations (Coronavirus Economic Response) Determination (No. 1) 2020, no hard copy of the Notice of Annual General Meeting and Explanatory Memorandum will be circulated, and shareholders have instead been notified of how to access the Notice of Annual General Meeting and Explanatory Memorandum.

Bio-Gene Technology Limited
ACN 071 735 950
Notice of Annual General Meeting

Notice is given that the 2020 Annual General Meeting of the members of Bio-Gene Technology Limited (**Bio-Gene** or the **Company**) will be held by audio-conference on Thursday, **26 November 2020** at 11am (Melbourne time) for the purpose of considering and, if thought appropriate, passing the following resolutions.

General Business

1. Receipt and Consideration of 2020 Financial Statements and Reports

To receive and consider the Financial Statements of the Company and its controlled entities for the year ended 30 June 2020, together with the Directors' Report (other than Remuneration Report) and the Independent Audit Report as set out in the Annual Report 2020.

2. Resolution 1 – Adoption of Remuneration Report (Non-Binding Resolution)

To consider, and if thought fit, to pass the following resolution as an ordinary resolution*:

"To adopt the Remuneration Report for the year ended 30 June 2020 as set out in the Annual Report 2020".

**Please note that Section 250R(3) of the Corporations Act 2001 (Cth) provides that the vote on this resolution is advisory only and does not bind the Directors or the Company.*

3. Resolution 2 – Re-election of Mr. Donald Brumley as a Director

To consider, and if thought fit, to pass the following resolution as an ordinary resolution:

"That pursuant to clause 59(1) of the Company's Constitution, the members of the Company approve the re-appointment of Mr. Donald Brumley as a Director of the Company who, pursuant to clause 59(1)(b) is retiring by rotation and, being eligible, offers himself for re-election."

4. Resolution 3 – Re-election of Mr. Kevin Rumble as a Director

To consider, and if thought fit, to pass the following resolution as an ordinary resolution:

"That pursuant to clause 59(1) of the Company's Constitution, the members of the Company approve the re-appointment of Mr. Kevin Rumble as a Director of the Company who, pursuant to clause 59(1)(b) is retiring by rotation and, being eligible, offers himself for re-election."

Special Business

5. Resolution 4A – Ratification of the Prior Issue of Shares

To consider, and if thought fit, pass the following resolution as an ordinary resolution:

"That, for the purposes of ASX Listing Rule 7.4 and all other purposes, the members of the Company approve and ratify the Company's allotment and issue on 3 June 2020 of 14,030,003 fully paid ordinary shares to unrelated professional and sophisticated investors identified by the Company at an issue price of 15.5 cents per share on the terms and conditions set out in the Explanatory Notes which accompany the Notice of Meeting."

6. Resolution 4B – Ratification of the Prior Issue of Shares

To consider, and if thought fit, pass the following resolution as an ordinary resolution:

"That, for the purposes of ASX Listing Rule 7.4 and all other purposes, the members of the Company approve and ratify the Company's allotment and issue on 16 June 2020 of 1,457,742 fully paid ordinary shares to unrelated professional and sophisticated investors identified by the Company at an issue price of 15.5 cents per share on the terms and conditions set out in the Explanatory Notes which accompany the Notice of Meeting."

7. Resolution 5 – Approval of Executive Share Option Plan

To consider and, if thought fit, to pass the following resolution as an ordinary resolution:

“That, for the purposes of ASX Listing Rule 7.2 exception 13 and for all other purposes shareholders approve the adoption of the Company’s Executive Share Option Plan (**ESOP**) (copies of the ESOP Rules are available for inspection at the Company’s registered office) on the terms and conditions set out in the Explanatory Notes which accompany the Notice of Meeting.”

8. Resolution 6 – Issue of 5,000,000 options to Mr. Richard Jagger, Managing Director, under Executive Share Option Plan

To consider, and if thought fit, pass the following resolution as an ordinary resolution:

“That for the purposes of ASX Listing Rule 10.14, and for all other purposes approval be given for the Company to issue to Mr. Jagger (and/or his nominee(s)), 5,000,000 unlisted options (each with an exercise price which is the greater of 30 cents or 145% of the volume weighted average closing price for the 5 trading days before the date of issue of the options, expiring 4 years from issue and which, upon exercise, entitle the holder to a fully paid ordinary share in the capital of the Company) as set out in the Explanatory Notes which accompany the Notice of Meeting.”

9. Resolution 7 – Issue of 1,500,000 options to Mr. Peter May, Executive Director Research and Development, under Executive Share Option Plan

To consider, and if thought fit, pass the following resolution as an ordinary resolution:

“That for the purposes of ASX Listing Rule 10.14, and for all other purposes, approval be given for the Company to issue to Mr. May (and/or his nominee(s)), 1,500,000 unlisted options (each with an exercise price which is the greater of 30 cents or 145% of the volume weighted average closing price for the 5 trading days ending before the date of issue of the options, expiring 4 years from issue and which, upon exercise, entitle the holder to a fully paid ordinary share in the capital of the Company) as set out in the Explanatory Notes which accompany the Notice of Meeting.”

10. Resolution 8 – Listing Rule 7.1A (Placement of Additional Securities)

To consider, and if thought fit, pass the following resolution as a special resolution:

“That approval be given for the issue of equity securities of the Company, under and pursuant to ASX Listing Rule 7.1A, up to the maximum permitted under ASX Listing Rule 7.1A.2 over a 12 month period at an issue price which is not less than the minimum issue price calculated in accordance with the formula prescribed in ASX Listing Rule 7.1A.3 and on the terms set out in the Explanatory Notes which accompanied and formed part of the Notice of Meeting.”

11. Resolution 9: Amendment of Constitution

To consider, and if thought fit, pass the following resolution as a special resolution:

“That, for the purposes of section 136(2) of the Corporations Act 2001 (Cth) and for all other purposes, the constitution of the Company be amended as set out in Annexure A of the Memorandum which accompanied and formed part of the Notice of Meeting with effect immediately upon the passing of this Resolution.”

By order of the Board:



Roger McPherson
Company Secretary
23 October 2020

The accompanying Explanatory Notes and Proxy and Voting Instructions form part of this Notice.

Proxy and Voting Instructions

VOTING VIRTUALLY AT THE MEETING

Shareholders who wish to vote virtually on the day of the AGM will need to login to the Automic website (<https://investor.automic.com.au/#/home>) with their *username* and *password*.

Shareholders who do not have an account with Automic are encouraged to register for an account **as soon as possible** to avoid any delays on the day of the Meeting.

How do I create an account with Automic?

To create an account with Automic, please go to the Automic website (<https://investor.automic.com.au/#/home>), click on 'register' and follow the steps. Shareholders will require their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) to create an account with Automic.

I have an account with Automic

Shareholders who have an existing account with Automic should take the following steps to attend and vote virtually on the day of the AGM:

- Login to the Automic website (<https://investor.automic.com.au/#/home>) using your username and password.
- If registration for the virtual meeting is open, click on 'Meeting open for registration' and follow the steps.
- If live voting for the virtual meeting is open, click on 'Meeting open for voting' and follow the steps.

PROXY INSTRUCTIONS

A member who is entitled to vote at a meeting may appoint:

- one proxy if the member is only entitled to one vote; and
- one or two proxies if the member is entitled to more than one vote.

Where more than one proxy is appointed each proxy may be appointed to represent a specific proportion of the member's voting rights. If the appointment does not specify the proportion or number of votes each proxy may exercise, each proxy may exercise half of the votes in which case any fraction of votes will be disregarded.

The proxy form (and the power of attorney or other authority, if any, under which the proxy form is signed) or a copy or facsimile which appears on its face to be an authentic copy of the proxy form (and the power of attorney or other authority) must be lodged not less than 48 hours before the time for holding the Meeting, or adjourned meeting as the case may be, at which the individual named in the proxy form proposes to vote. The proxy form must be signed by the member or his/her attorney duly authorised in writing or, if the member is a corporation, in a manner permitted by the Corporations Act. A proxy given by a foreign corporation must be executed in accordance with the laws of that corporation's place of incorporation.

The proxy may be a member of the Company.

A proxy form is attached to this Notice.

If you sign the proxy form and do not appoint a proxy, you will have appointed the Chair of the meeting as your proxy.

CORPORATE REPRESENTATIVES

Any corporation which is a member of the Company may appoint a proxy, as set out above, or authorise (by certificate under common seal or other form of execution authorised by the laws of that corporation's place of incorporation, or in any other manner satisfactory to the chairperson of the Meeting) a natural person to act as its representative at any general meeting.

Corporate representatives are requested to bring appropriate evidence of appointment as a representative in accordance with the constitution of the Company. Attorneys are requested to bring the original or a certified copy of the power of attorney pursuant to which they were appointed. Proof of identity will also be required for corporate representatives and attorneys.

HOW THE CHAIR WILL VOTE UNDIRECTED PROXIES

Subject to the restrictions set out below and in the Explanatory Notes, The Chair of the meeting intends to vote undirected proxies on, and in favour of, all of the proposed resolutions.

UNDIRECTED PROXIES

The Corporations Act imposes prohibitions on Key Management Personnel (as defined in the Explanatory Notes) and their Closely Related Parties from voting undirected proxies (i.e. a proxy that does not specify how it is to be voted) on, amongst other things, remuneration matters. Resolutions 1, 5, 6 and 7 are connected, directly or indirectly, with the remuneration of Key Management Personnel of the Company.

However, the Chair of the meeting may vote an undirected proxy, provided the shareholder who has lodged the proxy has given an express voting direction to the Chair to exercise the undirected proxy, even if the resolution is connected with the remuneration of a member of the Key Management Personnel.

If you complete a proxy form that authorises the Chair of the Meeting to vote on your behalf as proxy, and you do not mark any boxes so as to give him directions about how your vote should be cast, then you will be taken to have expressly authorised the Chair to exercise your proxy on Resolutions 1, 5, 6 and 7. In accordance with this express authority provided by you, the Chairman will vote in favour of Resolutions 1, 5, 6 and 7. If you wish to appoint the Chair as your proxy, and you wish to direct him how to vote, please tick the appropriate boxes on the Proxy Form attached to this Notice. Further details of the voting exclusions with respect to Resolutions 1, 5, 6 and 7 are set out in the Explanatory Notes.

VOTING ENTITLEMENT

For the purposes of the Corporations Act and Corporations Regulations shareholders entered on the Company's Register of Members as at 7.00 pm on Tuesday 24 November 2020 are entitled to attend and vote at the meeting.

On a poll, members have one vote for every fully paid ordinary share held. Holders of options are not entitled to vote.

SPECIAL RESOLUTIONS

For a special resolution to be passed, at least 75% of the votes validly cast on the resolution by shareholders (by number of shares) must be in favour of the resolution. Resolutions 8 and 9 are special resolutions.

Bio-Gene Technology Limited
ACN 071 735 950

Explanatory Notes

These Explanatory Notes have been prepared to provide members with information to assist their assessment of the merits of the resolutions contained in the accompanying notice of the Bio-Gene 2020 Annual General Meeting (**AGM or Meeting**) to be held by audio-conference on Thursday, **26 November 2020** at 11am (Melbourne time).

Please refer to the note on the front cover of the Notice of Annual General Meeting regarding COVID-19 related restrictions, lodging proxies and/or attending the Meeting virtually.

Shareholders are strongly encouraged to lodge their completed proxy forms in accordance with the instructions set out therein to vote before the Meeting.

General Business

1. Receipt and Consideration of 2020 Financial Statements and Reports

Section 317 of the Corporations Act requires the Financial Report, the Directors' Report (other than Remuneration Report) and the Auditor's Report for the year ended 30 June 2020 to be laid before the AGM. There is no requirement either in the Corporations Act or in the Company's Constitution for members to approve these reports. Members will have a reasonable opportunity at the meeting to ask questions and comment on these reports and on the Company's business and operations.

The Company's Financial Statements and Reports are set out in the Company's 2020 Annual Report which can be obtained from the Company's website, <https://bio-gene.com.au/wp-content/uploads/2020/09/BGT-2020-Annual-Report-Final.pdf>.

Members should note that the Financial Statements and Reports will be received in the form presented. It is not the purpose of the AGM that the Financial Statements and Reports be accepted, rejected or modified in any way and accordingly there will be no formal resolution put to the AGM.

2. Resolution 1 - Adoption of Remuneration Report (Non-binding Resolution)

The 2020 Remuneration Report, which explains the Board's policies in relation to the nature and level of remuneration paid to Directors and senior management (**Key Management Personnel or KMP**) of the Company and which sets out remuneration details for each KMP, forms part of the Directors' Report on pages 15 to 24 (inclusive) of the Annual Report for the year ended 30 June 2020 which is available on the Company's website <http://bio-gene.com.au/wp-content/uploads/2020/09/BGT-2020-Annual-Report-Final.pdf>. A copy of the Annual Report has been sent to members who requested it with this Notice of Meeting and Explanatory Notes. A copy can also be obtained from the Company's website as outlined above.

The 2020 Remuneration Report:

- explains the Board's policies in respect of the nature and level of remuneration paid to each KMP of the Company;
- makes clear that remuneration is linked to performance of key executives and the Company overall;
- sets out the remuneration details for each KMP; and
- makes clear that the basis for remunerating Non-executive Directors is distinct from the basis for remunerating executives and Executive Directors.

As required under section 250R(2) of the Corporations Act, a resolution will be put to members to adopt the 2020 Remuneration Report. Members should note that the vote on this resolution is advisory only and is not binding on the Board or the Company. Members will be given the opportunity to ask questions about or make comments on the 2020 Remuneration Report.

Less than 25% of the votes cast on the corresponding resolution at the 2019 AGM were against adoption of the 2019 Remuneration Report.

If 25% or more of the votes cast on this Resolution are against adoption of the 2020 Remuneration Report, the Company will be required to consider, and report to members on, what action (if any) has been taken to address members' concerns at the 2021 AGM. If 25% or more of the votes cast at the 2021 AGM are against adoption of the Company's 2021 Remuneration Report, members may be required to consider a resolution to call another general meeting in accordance with the Corporations Act at which the Directors who held office at the date of the Directors' Report (excluding the Managing Director) will be required to seek re-election.

As the Directors are excluded from voting, they make no recommendation to the shareholders in respect of Resolution 1.

In accordance with the Corporations Act, a member of the Company's KMP and closely related parties of a KMP will not be eligible to vote on Resolution 1, except if the person:

- (a) votes as a proxy for a person who is entitled to vote, in accordance with the directions on the proxy form; and
- (b) the vote is not cast on behalf of a person who is KMP or a closely related party of a KMP.

The Chair may also exercise undirected proxies if the vote is cast on behalf of a person entitled to vote and the proxy appointment expressly authorises the Chair to exercise the proxy even if Resolution 1 is connected directly or indirectly with the remuneration of the KMP of the Company. The Chair, in their capacity as proxy holder, intends to vote all undirected proxies in favour of this Resolution 1.

3. Resolution 2 – Re-election of Mr. Donald Brumley as a Director

Clause 59(2) of the Constitution of the Company and ASX Listing Rule 14.4 provide that no Director, except the Managing Director, may hold office for a period in excess of 3 years, or beyond the third AGM following the Director's election, whichever is the longer, without submitting himself or herself for re-election. Clause 59(1) provides that at each AGM one-third of the previously elected Directors, and if their number is not a multiple of three, then the number nearest to but not exceeding one-third, must retire from office and are eligible for re-election.

Clause 59(1)(a) provides that the Directors to retire in every year under clause 59(1) are the Directors longest in office since last being elected. Clause 59(1)(b) provides that Directors elected on the same day may agree among themselves or determine by lot which of them must retire.

All Directors, except Mr Robert Klupacs were elected by the members as Directors at the Bio-Gen 2017 AGM held on 6 September 2017. Mr Robert Klupacs was elected by the members as a Director at the Bio-Gen 2018 AGM held on 20 November 2018. Mr Peter May was re-elected by the members as a Director at the Bio-Gen 2019 AGM held on 26 November 2019.

In accordance with clause 59(2) of the Constitution of the Company, Non-Executive Directors (Mr. Brumley and Mr. Rumble) must retire at this AGM. Being eligible for re-election Mr. Brumley has submitted himself for re-election at the Bio-Gen 2020 AGM.

A summary of Mr. Brumley's experience, qualifications and background is provided on page 12 of the Company's 2020 Annual Report, a copy of which is available on the ASX website (www.asx.com.au) or at <http://bio-gene.com.au/wp-content/uploads/2020/09/BGT-2020-Annual-Report-Final.pdf>.

4. Resolution 3 – Re-election of Mr. Kevin Rumble as a Director

Clause 59(2) of the Constitution of the Company and ASX Listing Rule 14.4 provide that no Director, except the Managing Director, may hold office for a period in excess of 3 years, or beyond the third AGM following the Director's election, whichever is the longer, without submitting himself or herself for re-election. Clause 59(1) provides that at each AGM one-third of the

previously elected Directors, and if their number is not a multiple of three, then the number nearest to but not exceeding one-third, must retire from office and are eligible for re-election.

Clause 59(1)(a) provides that the Directors to retire in every year under clause 59(1) are the Directors longest in office since last being elected. Clause 59(1)(b) provides that Directors elected on the same day may agree among themselves or determine by lot which of them must retire.

All Directors, except Mr Robert Klupacs were elected by the members as Directors at the Bio-Gene 2017 AGM held on 6 September 2017. Mr Robert Klupacs was elected by the members as a Director at the Bio-Gene 2018 AGM held on 20 November 2018. Mr Peter May was re-elected by the members as a Director at the Bio-Gene 2019 AGM held on 26 November 2019.

In accordance with clause 59(2) of the Constitution of the Company, Non-Executive Directors (Mr. Brumley and Mr. Rumble) must retire at this AGM. Being eligible for re-election Mr. Rumble has submitted himself for re-election at the Bio-Gene 2020 AGM.

A summary of Mr. Rumble's experience, qualifications and background is provided on page 13 of the Company's 2020 Annual Report, a copy of which is available on the ASX website (www.asx.com.au) or at <http://bio-gene.com.au/wp-content/uploads/2020/09/BGT-2020-Annual-Report-Final.pdf>.

Special Business

5. Resolutions 4A and 4B – Ratification of the Prior Placement of Shares

Resolutions 4A and 4B seek Shareholder ratification pursuant to ASX Listing Rule 7.4 for previous issues and allotments of an aggregate of 15,487,745 fully paid ordinary shares at a price of 15.5 cents per share as a placement to unrelated sophisticated and professional investors who were identified by the Company as part of its investor relations activities (**Share Placement**).

The shares under the Share Placement were issued in two tranches as set out below:

- 14,030,003 shares issued on 3 June 2020. An Appendix 2A was released to ASX on that date. These shares are the subject of Resolution 4A.
- 1,457,742 shares issued on 16 June 2020. An Appendix 2A was released to ASX on that date. These shares are the subject of Resolution 4B.

5.1 Details of the Previous Issues of Shares

The Share Placement, which was announced on 26 May 2020, closed in two tranches on 3 June and 16 June 2020 raising a total of \$2,400,600. The Company issued a total of 15,487,745 fully paid ordinary shares at a price of 15.5 cents.

The following is noted in respect of the Share Placement:

- Of the 14,030,003 shares issued on 3 June 2020, the Company issued 743,278 of these shares utilising its capacity under Listing Rule 7.1 and 13,286,725 of these shares utilising its capacity under Listing Rule 7.1A.
- The Company issued the 1,457,742 shares on 16 June 2020 utilising its capacity under Listing Rule 7.1.

Under Listing Rule 7.1, the Company may in any 12-month rolling period issue up to 15% of its ordinary share capital without prior shareholder approval. Under Listing Rule 7.1A the Company may in the period specified by Listing Rule 7.1A.1 issue up to 10% of its ordinary share capital without prior shareholder approval. The ability to utilise Listing Rule 7.1A is subject to shareholder approval which the Company obtained at its 2019 annual general meeting on 26 November 2019.

The Company issued the shares under the Share Placement pursuant to its (then unused) entitlement under ASX Listing Rules 7.1 and 7.1A and therefore did not require prior shareholder approval.

ASX Listing Rule 7.4 permits a company to obtain ratification from its shareholders in relation to a prior share issue. Resolutions 4A and 4B in combination seek shareholder ratification of the issue of the 15,487,745 shares that were issued as part of the Share Placement.

5.2 Information required under ASX Listing Rules 7.5

The ASX Listing Rules set out a number of regulatory requirements that must be satisfied in relation to the ratification of a prior issue of securities. ASX Listing Rule 7.5 requires that the meeting documents concerning a proposed resolution to approve the prior issue in accordance with ASX Listing Rule 7.4 must include the following information:

- The names of the allottees or the basis upon which the allottees were determined
The allottees were unrelated professional and sophisticated investors identified by the Company as part of its investor relations activities.
- The number of securities allotted and the date or dates on which the securities were allotted:
An aggregate of 15,487,745 fully paid ordinary shares across two tranches as set out below:
 - *14,030,003 shares issued on 3 June 2020. An Appendix 2A was released to ASX on that date. These shares are the subject of Resolution 4A.*
 - *1,457,742 shares issued on 16 June 2020. An Appendix 2A was released to ASX on that date. These shares are the subject of Resolution 4B.*
- The issue price at which the securities were allotted:
15.5 cents per share
- The terms of the securities:
Shares issued were fully paid ordinary shares ranking equally in all respects with all other fully paid ordinary shares then on issue in the Company
The use (or intended use) of the funds raised:
 - *Continue and expand commercialisation discussions;*
 - *Accelerate registration enabling studies;*
 - *Enable additional research on product efficacy and Mode of Action; and*
 - *General working capital.*
- A voting exclusion statement is contained below in item 5.5.

5.3 Effect of Resolutions 4A and/or 4B

If shareholders:

- Pass Resolutions 4A and 4B, the shares issued under the Share Placement will be treated as not having used the placement capacity of the Company under the Listing Rules and the Company will be able to issue equity securities using the refreshed placement capacity without shareholder approval.
- Pass either Resolution 4A or 4B, the shares issued under the Share Placement for which shareholder ratification is obtained will be treated as not having used the placement capacity of the Company under the Listing Rules and the Company will be able to issue equity securities using the refreshed placement capacity without shareholder approval. Those shares issued under the Share Placement for which shareholder ratification is not obtained will continue to use the placement capacity of the Company under the Listing Rules.
- Do not pass Resolutions 4A and 4B, all of the shares issued under the Share Placement will continue to use the placement capacity of the Company under the Listing Rules.

5.4 Recommendation for Resolutions 4A and 4B

The Company's directors unanimously recommend that shareholders approve Resolutions 4A and 4B.

5.5 Voting Exclusion Statement – Resolutions 4A and 4B

The Company will disregard any votes cast in favour of Resolutions 4A and 4B respectively by or on behalf of any person who participated in the issue under Resolutions 4A and 4B respectively or any associates of that person.

However, this does not apply to a vote cast in favour of this Resolution by:

- a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with the directions given to the proxy or attorney to vote on the resolution that way; or
- the chair of the meeting as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the chair to vote on this Resolution as the chair decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of the beneficiary provided the following conditions are met:
 - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the resolution; and
 - the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

6. Resolution 5 – Adoption of Executive Share Option Plan

6.1 Background

The Board is committed to incentivising and retaining the Company's Directors, executives and employees in a manner which promotes alignment of their interests with shareholder interests. Additionally, the Board considers equity-based compensation an integral component of the Company's remuneration platform as it allows it to be fiscally prudent by conserving cash resources while still enabling it to offer market-competitive remuneration arrangements.

At the 2019 AGM members approved the Loan Share Plan (**LSP**). The Board has now conducted a review of comparative companies in similar industries and has determined that it is more appropriate to issue options to executives and employees for their Long Term Incentive (**LTI**) rather than shares under the LSP.

Accordingly, the Board now seeks to obtain member approval for the Bio-Gene Executive Share Option Plan (**ESOP**). The ESOP is regarded as an *employee incentive scheme* for the purposes of Listing Rule 7.2. A copy of the ESOP will be provided without charge to members on request.

Approval of the ESOP and any options to be issued pursuant to the ESOP is sought pursuant to Listing Rule 7.2, Exception 13. Further details relating to Listing Rules requirements are set out in clause 6.2 below.

The ESOP is intended to enable participants to share in any increase in the Company's value (as measured by the share price) beyond the date of allocation of the options. A summary of the ESOP is set out later in these Notes.

Any issue of shares under the ESOP to Directors, or their associates, will still require approval by members under Listing Rule 10.14.

6.2 ASX Listing Rules

Listing Rule 7.1 provides generally that a company may not issue shares or securities convertible into shares equal to more than 15% of the company's issued share capital in any consecutive 12 month period without prior obtaining shareholder approval, unless the issue fits into one of the exceptions contained in Listing Rule 7.2. Listing Rule 7.2 exception 13 effectively provides that securities issued pursuant to an employee incentive scheme are not included in the calculation of the 15% for Listing Rule 7.1 purposes provided the employee incentive scheme and the securities to be issued pursuant to the ESOP have been approved by members within the previous 3 years.

Accordingly, shareholder approval is sought pursuant to this Resolution 5 in order for the Company to be able to issue options pursuant to the ESOP and have those options qualify under Listing Rule 7.2 exception 13 for 3 years from the date of approval.

The Board intends that the issue of options under the ESOP not be included when undertaking the calculation of the 15% limit pursuant to Listing Rule 7.1. Accordingly, the Company is seeking member approval of the ESOP so that the issue of options pursuant to the ESOP will qualify as an exception to Listing Rule 7.1 under exception 13 to Listing Rule 7.2.

6.3 Information required for Listing Rule 7.2, exception 13

Listing Rule 7.2, exception 13 requires the information detailed in Sections 6.3(a), (b), (c) and (d) to be provided to members:

(a) *Summary of Terms and Conditions of the Company's Executive Share Option Plan*

Selected employees of the Company and the Directors (collectively the **Participants**) are eligible to participate in the ESOP at the absolute discretion of the Company's Board of Directors (**Board**).

The vesting date, expiry date, exercise price and exercise period in relation to an option issued under the ESOP are determined by the Board in its discretion.

The above is only a summary of the main features of the ESOP. A full copy of the ESOP is available for inspection at the Company's registered office and will be provided without charge to shareholders on request.

(b) *Securities issued under the ESOP since last approval*

The ESOP has not previously been approved by shareholders and no securities have been issued under the ESOP. It is noted that the Company proposes issuing the unlisted options to subject of Resolutions 6 and 7 under the ESOP.

(c) *Maximum number of options proposed to be issued under the ESOP following the approval*

The Company proposes to issue a maximum of 12 million options under the ESOP if approved by members.

(d) *Voting Exclusion Statement*

The Company will disregard any votes cast in favour of Resolution 5 by or on behalf of a person who is eligible to participate in the ESOP and an associate of those persons.

However, this does not apply to a vote cast in favour of this Resolution by:

- a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with the directions given to the proxy or attorney to vote on the resolution that way; or
- the chair of the meeting as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the chair to vote on this Resolution as the chair decides; or

- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of the beneficiary provided the following conditions are met:
 - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the resolution; and
 - the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

6.4 Recommendation for Resolution 5

As the Directors of Bio-Gene are excluded from voting pursuant to the Listing Rules, they make no recommendation to the shareholders in respect of the ESOP.

The Chairman in his capacity as proxy holder intends to vote undirected proxies in favour of approving this Resolution 5.

6.5 Undirected proxies

In accordance with the Corporations Act, a member of the Company's KMP and closely related parties of a KMP will not be eligible to cast a vote as proxy on Resolution 5 except as set out below.

A member of the Company's KMP and closely related parties of the KMP may cast a vote on Resolution 5 as proxy if either:

- that person is appointed as proxy in writing that specifies the way the proxy is to vote on Resolution 5; or
- that person is the Chair of the meeting and the written appointment of the Chair as proxy:
 - does not specify the way the proxy is to vote on Resolution 5; or
 - expressly authorises the Chair to exercise the proxy even though Resolution 5 is connected directly or indirectly with the remuneration of a member of the Company's KMP.

7. Resolution 6 – Issue of 5,000,000 Options to Mr. Richard Jagger

7.1 Reason for issue and Board recommendation

Subject to member approval, the Board proposes to grant Mr. Richard Jagger 5,000,000 unlisted options, each with an exercise price which is the greater of 30 cents or 145% of the volume weighted average closing price for the 5 trading days before the date of issue of the options, expiring 4 years from issue and which, upon exercise, entitle the holder to one fully paid ordinary shares in the capital of the Company. If approved by shareholders, the unlisted options would be proposed to be issued to Mr. Jagger and/or his nominee(s).

The unlisted options proposed to be issued to Mr. Jagger are subject to the following vesting conditions:

- 833,333 unlisted options vest on the date that is 1 year from issue.
- 833,333 unlisted options vest on the date that is 2 years from issue.
- 833,334 unlisted options vest on the date that is 3 years from issue.
- 2,500,000 unlisted options vest at such time as the Company's closing share price on the ASX has been at least 30 cents for 30 consecutive trading days.

If Mr. Jagger ceases to be an employee of the Company, all options that are not vested lapse upon the date of such cessation. In the case of unexercised vested options, Mr. Jagger will, subject to the discretion set forth in the ESOP, have a six month period from the date of the termination of his employment to exercise those options.

The full terms of the options are described in clause 7.3 below.

Under the terms of the previous Long Term Incentive plan (**LTI**), Mr Jagger was eligible to receive shares under the LSP valued at 25% of his total potential remuneration (base salary, superannuation, Short term incentive (**STI**) and LTI). These shares were issued effective at the commencement of each financial year. Half of these shares were issued based on the 5 day VWAP (volume weighted average price) of the Company's shares as at June 30 of the relevant year for nominal value, vesting in three equal tranches on July 1 of the following 3 years subject to achievement of share price targets. The other half of these shares were issued based on the 5 day VWAP (volume weighted average price) of the Company's shares as at June 30 of the relevant year, priced at that price with a limited recourse loan provided for the purchase. These shares were subject to vesting on the third anniversary of the issue date if commercial targets had been achieved. Full details of these arrangements are outlined in the Remuneration Report contained in the Company's 2020 Annual Report.

The Board has determined that this remuneration structure was overly complicated and agreed to replace the LTI component with this issue of options under the ESOP. It is proposed to make a single issue of options to the executives as a replacement of the LTI moving forward. The exercise price of the options will align the executives' interests with the interest of Shareholders.

The Board considers the grant of the 5,000,000 options to Mr. Jagger, on the terms proposed in Resolution 6, to be reasonable and in accordance with his employment agreement as Chief Executive Officer and Managing Director.

The Board views the grant as being in line with corporate remuneration of similar companies.

The options will be issued under the terms of the ESOP as detailed in the Explanatory Notes to resolution 5 of this Notice of Meeting.

The Board has, subject to member approval, resolved to issue Mr. Jagger the options at an exercise price which is the greater of 30 cents (which is a premium of 87.5% to the closing share price on 22 October 2020) or 145% of the volume weighted average closing price for the 5 trading days before the date of issue of the options.

The Board (except for Mr. Jagger) unanimously recommends that members vote in favour of this Resolution 6.

7.2 Chapter 2E of the Corporations – Related Party Transactions

Under Chapter 2E of the Corporations Act, a public company cannot give a "financial benefit" to a "related party" unless one of the exceptions to section 208 of the Corporations Act apply or members have in general meeting approved the giving of that financial benefit to the related party.

Section 211 of the Corporations Act provides that an entity does not need to obtain member approval to give a financial benefit to a related party if the giving of the financial benefit would be reasonable given:

- (a) the circumstances of the Company; and
- (b) the related party's circumstances (including the responsibilities involved in the office or employment).

The Company considers the proposed issue is reasonable remuneration and, as such, fall within the exception set out in section 211 of the Corporations Act.

In reaching this view, the Company has considered the position and responsibilities of Mr. Jagger, the need for the Company to effectively incentivize the Directors to attract and retain high calibre

staff while aligning the incentive with increasing shareholder value, and the Company's decision to move away from short-term incentive payments and further explore incentives that are linked with long term growth. The Company considers that the issue of unlisted options is an effective tool which preserves the cash reserves of the Company whilst providing valuable consideration for Mr. Jagger.

Mr. Jagger was not present during any discussions and/or determination on the proposed issue of unlisted options to him and/or his nominee(s). Following issue of the unlisted options the subject of Resolution 6, Mr. Jagger will have a relevant interest in 5,000,000 unlisted options.

7.3 ASX Listing Rules

If shareholders approve Resolution 6 then the Company will be able to issue the 5,000,000 unlisted options to Mr. Jagger (and/or his nominee(s)). If unlisted options are issued and are exercised into ordinary shares, the placement capacity of the Company to issue equity securities under ASX Listing Rule 7.1 and, subject to the relevant shareholder approval being held at the time, ASX Listing Rule 7.1A, will be increased. If shareholders do not pass Resolution 6 then the Company will not be able to issue the unlisted options to Mr Jagger.

In order for a listed company to obtain the approval of ordinary members as required by ASX Listing Rule 10.14, ASX Listing Rule 10.15 requires that the notice in relation to a proposed resolution to approve an issue of securities to a related party, include the following information:

- The name and role of the person to whom the securities will be issued:
Mr. Richard Jagger, the Managing Director and CEO of the Company (and/or his nominee(s)).
- Which category in rules 10.14.1 – 10.14.3 the person falls within and why.
Mr. Richard Jagger is the Managing Director of the Company and therefore falls within Listing Rule 10.14.1.
- The number and class of securities to be issued to the person under the ESOP:
5,000,000 unlisted options.
- Details of Mr. Richard Jagger's current total remuneration package:
Mr. Jagger receives \$268,954 per annum including superannuation plus a short term incentive (STI) of up to a maximum of \$134,477 per annum for acting as Managing Director and CEO of the Company.
- The number of securities previously issued to Mr Richard Jagger under the ESOP & the average acquisition price paid:
As at the date of this Notice, no securities have been issued to Mr. Jagger under the ESOP.
- Summary of the material terms of the unlisted options:
 - (i) *The exercise price of each option will be the greater of 30 cents or 145% of the volume weighted average closing price for the 5 trading days before the date of issue of the options. The options will be issued for nil consideration with the shares issued on exercise being credited as fully paid.*
 - (ii) *One-half of the options will vest in 3 tranches over 3 years and the balance will vest at such time as the Company's closing share price on the ASX has been at least 30 cents for 30 consecutive trading days, subject to Resolution 6 being passed by members.*
 - (iii) *All options, once vested, must be exercised on or behalf the fourth anniversary of the issue date of the option. If the option is not exercised during that period it will lapse.*
 - (iv) *If Mr. Jagger ceases to be an employee of the Company, all unexercised options that are not vested will lapse upon the date of such cessation. In the case of all*

unexercised vested options, Mr. Jagger will, subject to the discretions set forth in the ESOP, have a six month period from the date of the termination of his employment to exercise those options.

- (v) *All unexercised options will lapse upon the liquidation of the Company.*
- (vi) *If prior to the exercise of an option, there is a re-organisation of the Company's capital (including consolidation, subdivision, reduction, return or cancellation of the issued capital of the Company), then the exercise price or the number of outstanding options (or both) must be re-organised in accordance with the ASX Listing Rules applying to a re-organisation at the time of the re-organisation.*
- (vii) *The options may not be sold or transferred except with the prior written consent of the Company.*
- (viii) *An option does not confer the right to participate in new issues of capital offered to holders of ordinary shares of the Company without exercising the option.*
- (ix) *The shares issuing upon the exercise of an option will rank equally in all respects with all other issued ordinary shares of the Company from the date of the issue of those shares.*

As described above, unlisted options are proposed to be issued as reasonable remuneration to incentivise Mr. Jagger and to preserve the cash resources of the Company. The value attributed by the Company to the unlisted options is set out in clause 7.4 below.

- *The date by which the entity will issue the securities:
Subject to the resolution being passed by members, the Company proposes issuing the unlisted options within 45 business days after the Meeting.*
- *The issue price of the securities
The unlisted options are to be issued as remuneration for no cash consideration.*
- *A summary of the terms of the scheme:
The material terms of the ESOP are set out in clause 6.3(a).*
- *The intended use of the funds raised:
No funds will be raised from the issue of the unlisted options. The funds raised from the exercise of the options will be used as working capital for the Company.*
- *Loan details
The Company confirms that no loan will be made to Mr. Jagger in connection with the unlisted options.*
- *The Company confirms the following:
 - (i) *Details of any securities issued under the ESOP will be published in the Directors' Report contained in the annual report of the Company relating to the period in which they were issued, along with a statement that approval for the issue was obtained under ASX Listing Rule 10.14; and.*
 - (ii) *Any additional persons covered by ASX Listing Rule 10.14 who become entitled to participate in an issue of securities under the ESOP after these resolutions are approved and who were not named in the Notice will not participate until approval is obtained under ASX Listing Rule 10.14.**
- *A voting exclusion statement is set out in item 7.6 below.*

7.4 Valuation of options

The value of the options to be issued is not known at this stage. This Resolution 6 proposes that 5,000,000 unlisted options will be issued with an exercise price which is the greater of 30 cents or 145% of the volume weighted average closing price for the 5 trading days before the date of issue of the options.

The options are to be valued utilising an industry standard option pricing model taking into account the terms and conditions under which the options were issued.

While this is a recognised valuation model it includes certain assumptions for example regarding volatility of Bio-Gene shares. Bio-Gene has considered the historical or implied volatility of itself and similar listed entities, for which share price information is available and has used this share price volatility as a guide in valuing these options. A share with a greater volatility has a greater time value component of the total share value. After examining the volatility experienced by shares in Bio-Gene and similar listed entities, it was concluded that a share price volatility of 88.0% is appropriate when valuing these options. Another variable in the formula is the interest rate. For this purpose Bio-Gene will use the Government Bonds interest rate available from the Reserve Bank on the previous trading day before the date of issue for the term of the options.

To give members an indication of the value of the options that would be issued to Mr. Jagger if this resolution is approved, the indicative fair value of each option is provided below. These values are indicative only since an actual valuation can be determined only by reference to the Company's share price and the interest rates as at the date of issue. If the resolution is approved, the actual number of options issued will be announced to the market (as the Company will be required to lodge an Appendix 3Y after they have been issued) and disclosed as part of Mr. Jagger's remuneration in the Company's Annual Report for the year ending 30 June 2021.

Based on the following assumptions the indicative average valuation per option is \$0.0797 (being a total of \$398,500 for 5,000,000 options):

- current price of a Bio-Gene share (based on the closing share price on 22 October 2020) of 16 cents;
- an exercise price of \$0.30 (being the higher of 30 cents or 145% of the closing share price on 22 October 2020);
- one-half of the options will vest in 3 equal tranches over 3 years on the anniversaries of the date of issue;
- the balance of the options will vest on the first occurrence of the Bio-Gene closing share price on the ASX being 30 cents or more for 30 consecutive trading days prior to the fourth anniversary of the issue date. The Company notes that this may not occur at all;
- the options must be exercised, after vesting, on or before the fourth anniversary of the issue date;
- other assumptions as to risk free interest rates, volatility and dividend yields made in accordance with accepted valuation techniques as explained above; and
- no discount has been included for forfeiture of the options which might occur if Mr. Jagger ceases to be employed by the Company prior to the Bio-Gene share price exceeding the exercise price and the options having vested.

7.5 Recommendation for Resolution 6

The Directors (except for Mr. Jagger) unanimously recommend that members vote in favour of this Resolution 6.

The Chairman in his capacity as proxy holder intends to vote undirected proxies in favour of this Resolution 6.

7.6 Voting Prohibition under the Corporations Act and Voting Exclusion Statement under the ASX Listing Rules

In accordance with the Corporations Act, a member of the Company's KMP and closely related parties of a KMP will not be eligible to cast a vote as proxy on Resolution 6 except as set out below.

A member of the Company's KMP and closely related parties of the KMP may cast a vote on Resolution 6 as proxy if either:

- that person is appointed as proxy in writing that specifies the way the proxy is to vote on Resolution 6; or
- that person is the Chair of the meeting and the written appointment of the Chair as proxy:
 - does not specify the way the proxy is to vote on Resolution 6; or
 - expressly authorises the Chair to exercise the proxy even though Resolution 6 is connected directly or indirectly with the remuneration of a member of the Company's KMP.

The Company will disregard any votes cast in favour of Resolution 6 by or on behalf of a person referred to in rule 10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the ESOP and any associate of those persons.

However, this does not apply to a vote cast in favour of this Resolution by:

- a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with the directions given to the proxy or attorney to vote on the resolution that way; or
- the chair of the meeting as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the chair to vote on this Resolution as the chair decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of the beneficiary provided the following conditions are met:
 - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the resolution; and
 - the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

8. Resolution 7 – Issue of 1,500,000 Options to Mr. Peter May

8.1 Reason for issue and Board recommendation

Subject to member approval, the Board proposes to grant Mr. Peter May 1,500,000 unlisted options, each with an exercise price which is the greater of 30 cents or 145% of the volume weighted average closing price for the 5 trading days before the date of issue of the options, expiring 4 years from issue and which, upon exercise, entitle the holder to one fully paid ordinary shares in the capital of the Company. If approved by shareholders, the unlisted options would be proposed to be issued to Mr. May and/or his nominee(s).

The unlisted options proposed to be issued to Mr. May are subject to the following vesting conditions:

- 250,000 unlisted options vest on the date that is 1 year from issue.
- 250,000 unlisted options vest on the date that is 2 years from issue.
- 250,000 unlisted options vest on the date that is 3 years from issue.
- 750,000 unlisted options vest at such time as the Company's closing share price on the ASX has been at least 30 cents for 30 consecutive trading days.

If Mr. May ceases to be an employee of the Company, all options that are not vested lapse upon the date of such cessation. In the case of unexercised vested options, Mr. May will, subject to the discretion set forth in the ESOP, have a six month period from the date of the termination of his employment to exercise those options.

The full terms of the options are described in clause 8.3 below.

Under the terms of the previous LTI, Mr May was eligible to receive shares under the LSP valued at 15% of his total potential remuneration (base salary, superannuation, STI and LTI). These shares were issued effective at the commencement of each financial year. Half of these shares were issued based on the 5 day VWAP (volume weighted average price) of the Company's shares as at June 30 of the relevant year for nominal value, vesting in three equal tranches on July 1 of the following 3 years subject to achievement of share price targets. The other half of these shares were issued based on the 5 day VWAP (volume weighted average price) of the Company's shares as at June 30 of the relevant year, priced at that price with a limited recourse loan provided for the purchase. These shares were subject to vesting on the third anniversary of the issue date if commercial targets had been achieved. Full details of these arrangements are outlined in the Remuneration Report contained in the Company's 2020 Annual Report.

The Board has determined that this remuneration structure was overly complicated and agreed to replace the LTI component with this issue of options under the ESOP. It is proposed to make a single issue of options to the executives as a replacement of the LTI moving forward. The exercise price of the options will align the executives' interests with the interest of Shareholders.

The Board considers the grant of the 1,500,000 options to Mr. May, on the terms proposed in Resolution 7, to be reasonable and in accordance with his employment agreement as Executive Director, Research and Development.

The Board views the grant as being in line with corporate remuneration of similar companies.

The options will be issued under the terms of the ESOP as detailed in the Explanatory Notes to resolution 5 of this Notice of Meeting.

The Board has, subject to member approval, resolved to issue Mr. May the options at an exercise price which is the greater of 30 cents (which is a premium of 87.5% to the closing share price on 22 October 2020) or 145% of the volume weighted average closing price for the 5 trading days before the date of issue of the options.

The Board (except for Mr. May) unanimously recommends that members vote in favour of this Resolution 6.

8.2 Chapter 2E of the Corporations – Related Party Transactions

Under Chapter 2E of the Corporations Act, a public company cannot give a "financial benefit" to a "related party" unless one of the exceptions to section 208 of the Corporations Act apply or members have in general meeting approved the giving of that financial benefit to the related party.

Section 211 of the Corporations Act provides that an entity does not need to obtain member approval to give a financial benefit to a related party if the giving of the financial benefit would be reasonable given:

- (a) the circumstances of the Company; and
- (b) the related party's circumstances (including the responsibilities involved in the office or employment).

The Company considers the proposed issue is reasonable remuneration and, as such, fall within the exception set out in section 211 of the Corporations Act.

In reaching this view, the Company has considered the position and responsibilities of Mr May, the need for the Company to effectively incentivize the Directors to attract and retain high calibre staff while aligning the incentive with increasing shareholder value, and the Company's decision

to move away from short-term incentive payments and further explore incentives that are linked with long term growth. The Company considers that the issue of unlisted options is an effective tool which preserves the cash reserves of the Company whilst providing valuable consideration for Mr May.

Mr. May was not present during any discussions and/or determination on the proposed issue of unlisted options to him and/or his nominee(s). Following issue of the unlisted options the subject of Resolution 7, Mr. May will have a relevant interest in 1,500,000 unlisted options.

8.3 ASX Listing Rules

If shareholders approve Resolution 7 then the Company will be able to issue the 1,500,000 unlisted options to Mr. May (and/or his nominee(s)). If unlisted options are issued and are exercised into ordinary shares, the placement capacity of the Company to issue equity securities under ASX Listing Rule 7.1 and, subject to the relevant shareholder approval being held at the time, ASX Listing Rule 7.1A, will be increased. If shareholders do not pass Resolution 7 then the Company will not be able to issue the unlisted options to Mr. May.

In order for a listed company to obtain the approval of ordinary members as required by ASX Listing Rule 10.14, ASX Listing Rule 10.15 requires that the notice in relation to a proposed resolution to approve an issue of securities to a related party, include the following information:

- The name and role of the person to whom the securities will be issued:
Mr. Peter May, the Executive Director Research and Development of the Company (and/or his nominee(s)).
- Which category in rules 10.14.1 – 10.14.3 the person falls within and why.
Mr. Peter May is a Director of the Company and therefore falls within Listing Rule 10.14.1.
- The number and class of securities to be issued to the person under the ESOP:
1,500,000 unlisted options.
- Details of Mr. Peter May's current total remuneration package:
Mr. May receives \$208,019 per annum including superannuation plus a short term incentive (STI) of up to a maximum of \$44,575 per annum for acting as an Executive Director of the Company.
- The number of securities previously issued to Mr Peter May under the ESOP & the average acquisition price paid:
As at the date of this Notice, no securities have been issued to Mr. May under the ESOP.
- Summary of the materials terms of the unlisted options:
 - (i) *The exercise price of each option will be the greater of 30 cents or 145% of the volume weighted average closing price for the 5 trading days before the date of issue of the options. The options will be issued for nil consideration with the shares issued on exercise being credited as fully paid.*
 - (ii) *One-half of the options will vest in 3 tranches over 3 years and the balance will vest at such time as the Company's closing share price on the ASX has been at least 30 cents for 30 consecutive trading days, subject to Resolution 7 being passed by members.*
 - (iii) *All options, once vested, must be exercised on or behalf the fourth anniversary of the issue date of the option. If the option is not exercised during that period it will lapse.*
 - (iv) *If Mr. May ceases to be an employee of the Company, all unexercised options that are not vested will lapse upon the date of such cessation. In the case of all unexercised vested options, Mr. May will, subject to the discretions set forth in the*

Plan Rules, have a six month period from the date of the termination of his employment to exercise the options.

- (v) *All unexercised options will lapse upon the liquidation of the Company.*
- (vi) *If prior to the exercise of an option, there is a re-organisation of the Company's capital (including consolidation, subdivision, reduction, return or cancellation of the issued capital of the Company), then the exercise price or the number of outstanding options (or both) must be re-organised in accordance with the ASX Listing Rules applying to a re-organisation at the time of the re-organisation.*
- (vii) *The options may not be sold or transferred except with the prior written consent of the Company.*
- (viii) *An option does not confer the right to participate in new issues of capital offered to holders of ordinary shares of the Company without exercising the option.*
- (ix) *The shares issuing upon the exercise of an option will rank equally in all respects with all other issued ordinary shares of the Company from the date of the issue of those shares.*

As described above, unlisted options are proposed to be issued as reasonable remuneration to incentivise Mr. May and to preserve the cash resources of the Company. The value attributed by the Company to the unlisted options is set out in clause 8.4 below.

- The date by which the entity will issue the securities:
Subject to the resolution being passed by members, the Company proposes issuing the unlisted options within 45 business days after the Meeting.
- The issue price of the securities
The unlisted options are to be issued as remuneration for no cash consideration.
- A summary of the terms of the scheme:
The material terms of the ESOP are set out in clause 6.3(a).
- The intended use of the funds raised:
No funds will be raised from the issue of the unlisted options. The funds raised from the exercise of the options will be used as working capital for the Company.
- The Company confirms the following:
 - (i) *Details of any securities issued under the ESOP will be published in the Directors' Report contained in the annual report of the Company relating to the period in which they were issued, along with a statement that approval for the issue was obtained under ASX Listing Rule 10.14; and*
 - (ii) *Any additional persons covered by ASX Listing Rule 10.14 who become entitled to participate in an issue of securities under the ESOP after these resolutions are approved and who were not named in the Notice will not participate until approval is obtained under ASX Listing Rule 10.14.*
- A voting exclusion statement is set out in item 8.6 below.

8.4 Valuation of options

The value of the options to be issued is not known at this stage. This Resolution 7 proposes that 1,500,000 unlisted options will be issued with an exercise price which is the greater of 30 cents or 145% of the volume weighted average closing price for the 5 trading days before the date of issue of the options. The options are to be valued utilising an industry standard option pricing model taking into account the terms and conditions under which the options were issued.

While this is a recognised valuation model it includes certain assumptions for example regarding volatility of Bio-Gene shares. Bio-Gene has considered the historical or implied volatility of itself and similar listed entities, for which share price information is available and has used this share

price volatility as a guide in valuing these options. A share with a greater volatility has a greater time value component of the total share value. After examining the volatility experienced by shares in Bio-Gene and similar listed entities, it was concluded that a share price volatility of 88.0% is appropriate when valuing these options. Another variable in the formula is the interest rate. For this purpose Bio-Gene will use the Government Bonds interest rate available from the Reserve Bank on the previous trading day before the date of issue for the term of the options.

To give members an indication of the value of the options that would be issued to Mr. May if this resolution is approved, the indicative fair value of each option is provided below. These values are indicative only since an actual valuation can be determined only by reference to the Company's share price and the interest rates as at the date of issue. If the resolution is approved, the actual number of options issued will be announced to the market (as the Company will be required to lodge an Appendix 3Y after they have been issued) and disclosed as part of Mr. May's remuneration in the Company's Annual Report for the year ending 30 June 2021.

Based on the following assumptions the indicative average valuation per option is \$0.0797 (being a total of \$119,550 for 1,500,000 options):

- current price of a Bio-Gene share (based on the closing share price on 22 October 2020) of 16 cents;
- an exercise price of \$0.30 (being the higher of 30 cents or 145% of the closing share price on 22 October 2020);
- one-half of the options will vest in 3 equal tranches over 3 years on the anniversaries of the date of issue;
- the balance of the options will vest on the first occurrence of the Bio-Gene closing share price on the ASX being 30 cents or more for 30 consecutive trading days prior to the fourth anniversary of the issue date. The Company notes that this may not occur at all;
- the options must be exercised, after vesting, on or before the fourth anniversary of the issue date;
- other assumptions as to risk free interest rates, volatility and dividend yields made in accordance with accepted valuation techniques as explained above; and
- no discount has been included for forfeiture of the options which might occur if Mr. May ceases to be employed by the Company prior to the Bio-Gene share price exceeding the exercise price and the options having vested.

8.5 Recommendation for Resolution 7

The Directors (except for Mr. May) unanimously recommend that members vote in favour of this Resolution 7.

The Chairman in his capacity as proxy holder intends to vote undirected proxies in favour of this Resolution 7.

8.6 Voting Prohibition under the Corporations Act and Voting Exclusion Statement under the ASX Listing Rules

In accordance with the Corporations Act, a member of the Company's KMP and closely related parties of a KMP will not be eligible to cast a vote as proxy on Resolution 7 except as set out below.

A member of the Company's KMP and closely related parties of the KMP may cast a vote on Resolution 7 as proxy if either:

- that person is appointed as proxy in writing that specifies the way the proxy is to vote on Resolution 7; or
- that person is the Chair of the meeting and the written appointment of the Chair as proxy:
 - does not specify the way the proxy is to vote on Resolution 7; or

- expressly authorises the Chair to exercise the proxy even though Resolution 7 is connected directly or indirectly with the remuneration of a member of the Company's KMP.

The Company will disregard any votes cast in favour of Resolution 7 by or on behalf of a person referred to in rule 10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the ESOP and any associate of those persons.

However, this does not apply to a vote cast in favour of this Resolution by:

- a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with the directions given to the proxy or attorney to vote on the resolution that way; or
- the chair of the meeting as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the chair to vote on this Resolution as the chair decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of the beneficiary provided the following conditions are met:
 - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the resolution; and
 - the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

9. Resolution 8 – Listing Rule 7.1A (Placement of Additional Securities)

9.1 Background

By Resolution 8 the Company is seeking member approval, by special resolution, for the purposes of ASX Listing Rule 7.1A. Presently, the Company can issue up to 15% of its issued capital in any 12 month period without needing to seek member approval. Under ASX Listing Rule 7.1A, the Company can issue up to an additional 10% of its issued capital over a 12 month period if it obtains the prior approval of members. Upon receiving member approval, the equity securities issued pursuant to ASX Listing Rule 7.1A will not be included in the calculation of the Company's 15% entitlement under ASX Listing Rule 7.1.

9.2 Eligibility

In order to seek member approval under ASX Listing Rule 7.1A, the Company must have a market capitalisation of \$300 million or less, and not be included in the S&P/ASX 300 Index as at the date that the AGM is held.

If the Company does not meet the eligibility criteria on the date of the AGM, the special resolution will be withdrawn and members will not be required to vote on the resolution.

9.3 Information required under ASX Listing Rule 7.3A

ASX Listing Rule 7.3A requires that the following information be provided to members:

- the minimum price at which equity securities issued under ASX Listing Rule 7.1A may be issued:

no less than 75% of the volume weighted average price for the equity securities calculated over the 15 trading days on which trades in those equity securities were recorded immediately before:

 - (i) *the date on which the price at which the equity securities are to be issued is agreed by the Company and the recipient of the relevant equity securities; or*
 - (ii) *if the equity securities are not issued within 10 trading days of the date in paragraph (i), the date on which the equity securities are issued.*

- the final date by which the equity securities may be issued under ASX Listing Rule 7.1A:

The earlier to occur of:

- (i) 26 November 2021, the date being 12 months after the date of shareholder approval of Resolution 8 at the 2020 AGM;
- (ii) The date of the 2021 AGM; or
- (iii) The date of member approval of a transaction under ASX Listing Rule 11.1.2 (change of activities) or 11.2 (disposal of main undertaking)

- the purposes for which the equity securities may be issued under ASX Listing Rule 7.1A:

At the date of the Notice of Meeting the Company has not identified any persons to whom it intends to offer securities under Listing Rule 7.1A. In the event that the Company issues any shares under Listing Rule 7.1A, the funds raised from such an issue would be used by the Company to advance its lead products, support potential partnering arrangements and provide working capital.

- the Company's allocation policy for issues under ASX Listing Rule 7.1A:

At the date of the Notice of Meeting the Company has not identified any persons to whom it intends to offer securities under Listing Rule 7.1A. In the event that the Company issues any securities under Listing Rule 7.1A, those securities could be offered to existing or new security holders or both.

- members should be aware that if approval is given to the Company to issue the equity securities, existing ordinary security holders risk economic and voting dilution, including the risk that:

- (i) *the market price for the equity securities may be significantly lower on the actual issue date of the equity securities than on the date that members give approval under ASX Listing Rule 7.1A; and*
- (ii) *the equity securities may be issued at a price that is a discount to the market price for those equity securities on the issue date.*

- the table below shows the dilution of existing members on the basis of the current market price of the shares and the current number of ordinary securities.

The table also shows:

- (i) *two examples where the number of securities on issue has increased by 50% and 100% from the number currently on issue. The number of securities on issue may increase as a result of issue of ordinary securities that do not require member approval (for example, a pro rata entitlement issue) or future specific placements under Listing Rule 7.1 that are approved at a future meeting of members; and*
- (ii) *two examples of where the issue price of ordinary securities has decreased by 50% and increased by 50% as against the current market price.*

Number of Shares on Issue		Dilution		
		\$0.08 50% decrease in Issue Price	\$0.16 Issue Price	\$0.24 50% increase in Issue Price
153,633,357 (Current)	10% Voting Dilution	15,363,336	15,363,336	15,363,336
	Funds Raised	\$1,229,067	\$2,458,134	\$3,687,201
230,450,036 (50% increase)	10% Voting Dilution	23,045,004	23,045,004	23,045,004
	Funds Raised	\$1,843,600	\$3,687,201	\$5,530,801
307,266,714 (100% increase)	10% Voting Dilution	30,726,671	30,726,671	30,726,671
	Funds Raised	\$2,458,134	\$4,916,267	\$7,374,401

The table has been prepared on the following assumptions:

- (i) The Company issues the maximum number of equity securities available under the 10% Listing Rule 7.1A placement approval.
 - (ii) No options to acquire shares on issue in the Company are exercised into shares before the date of the issue of equity securities under ASX Listing Rule 7.1A.
 - (iii) The 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example as 10%.
 - (iv) The table does not show an example of the dilution that may be caused to a particular shareholder by reasons on placements under the 10% Listing Rule 7.1A placement approval, based on that shareholder's holding at the date of the meeting.
 - (v) The table shows only the effect of issues of equity securities under Listing Rule 7.1A, not under the 15% placement capacity under Listing Rule 7.1.
 - (vi) The issue of equity securities under the 10% Listing Rule 7.1A placement approval consists only of shares. If the issue of equity securities includes options, it is assumed that those options are exercised into shares for the purpose of calculating the voting dilution effect on existing shareholders.
 - (vii) The issue price of \$0.16 is the closing price of the Shares on the ASX on 22 October 2020.
- The Company previously obtained shareholder approval under ASX Listing Rule 7.1A at the 2019 AGM held on 26 November 2019. In the 12 months prior to the date of the 2020 AGM, the Company has issued 13,286,725 securities under the additional placement capacity under ASX Listing Rule 7.1A which was approved by shareholders at the 2019 AGM.
 - As at the date of this Notice of Meeting equity securities issued pursuant to Listing Rule 7.1A within the 12 month period preceding 26 November 2020 are set out in the table below:

Date of Issue	Number and Class of Equity Securities Issued	Issue Price	Closing Price*	Discount / Premium	Issued to / basis of issue	Use of funds
3/6/20	13,286,725 BGT	\$0.155	\$0.155	No discount or premium	Issued under Share Placement	Cash \$2,059,442 Spent: \$123,567 Remaining: \$1,935,875 Shares issued pursuant to Share Placement. Funds raised have been, or will be, allocated to continue and expand commercialisation discussions, accelerate registration enabling studies, enable additional research on product efficacy and Mode of Action and for general working capital

9.4 Voting majority

This Resolution 8 is a special resolution and, as a result, must be passed by at least 75% of all the votes cast by members entitled to vote (whether in person or by proxy, attorney or, in the case of a corporate member, by corporate representative).

9.5 Recommendation for Resolution 8

The Company's Directors unanimously recommend that members approve Resolution 8.

9.6 Voting Exclusion Statement

At the date of this Notice, the Company has not approached any particular existing shareholder or security holder or an identifiable class of existing security holders to participate in the issue of the equity securities. No existing shareholder's votes will therefore be excluded under the voting exclusion in the Notice.

10. Resolution 9: Amendment of constitution

It is proposed that the Constitution of the Company be amended as set out in Annexure A. The amendment is proposed to update the Constitution of the Company to reflect changes to the ASX Listing Rules which took effect 1 December 2019.

In particular, the amendment is proposed to specifically address the new terms of ASX Listing Rule 15.12 which, subject to transitional arrangements for existing listed entities, provides that the constitution of a listed entity must include specific text.

This specific text is set out in full in Annexure A. An outline of the impact of these changes is set out below:

- adding that, if restricted securities are in the same class as quoted securities, the holder will be taken to have agreed in writing that the restricted securities are to be kept on the entity's issuer sponsored sub-register and to have a holding lock applied for the duration of the escrow period applicable to those securities. This formalises prior requirements of ASX that each holder of restricted securities must sign a written restriction agreement with respect to those restricted securities; and
- adding that a holder of restricted securities will not be entitled to participate in any return of capital on those securities during the escrow period applicable to those securities except as permitted by the listing rules of ASX. This amendment contains similar content to ASX Listing Rule 7.24A which provides an entity must not return capital to holders of restricted securities; and
- other consequential drafting changes to clarify the application of ASX Listing Rule 15.12.

As the Company is already listed, any existing restricted securities on issue are subject to transitional arrangements. However, if the Company:

- undertakes a transaction requiring re-compliance with Chapters 1 & 2 of the ASX Listing Rules under ASX Listing Rule 11.1.3 (full re-compliance) involving the issue of restricted securities;
- issues restricted securities to a party referred to in ASX Listing Rule 10.1 for the acquisition of a substantial classified asset from that party,

it will be required to comply with the new terms of ASX Listing Rule 15.12 in respect of any of its restricted securities following the above transaction(s). Noting the above, the Company considers the Meeting an opportunity to update its Constitution to address the changes to the ASX Listing Rules as described above.

In addition to the amendment to the Constitution as described above, it is proposed that certain, clarifying amendments are also made to the Constitution as also set out in Annexure A.

Resolution 9 is a special resolution and therefore requires approval of 75% of the votes cast by Shareholders present and eligible to vote (in person, by proxy, by attorney or, in the case of a corporate shareholder, by a corporate representative).

The Directors of the Company unanimously recommend shareholders vote in favour of Resolution 9.

Further information

The Directors recommend members read these Explanatory Notes in full and, if desired, seek advice from their own independent financial or legal adviser as to the effect of the proposed resolutions before making any decision in relation to the proposed resolutions.

ANNEXURE A

CONSTITUTION AMENDMENTS

Amendment to reflect new ASX Listing Rule 15.12

Amendment of Article 94 of the Constitution of the Company by deleting Article 94 in full and substituting the following:

“94. RESTRICTED SECURITIES

At times when the Company’s shares are listed for quotation on the ASX, for so long as the Company has any restricted securities on issue and despite any other provision in this Constitution:

- (a) a holder of restricted securities must not dispose of, or agree or offer to dispose of, the securities during the escrow period applicable to those securities except as permitted by the Listing Rules or ASX;
- (b) if the securities are in the same class as quoted securities, the holder will be taken to have agreed in writing that the restricted securities are to be kept on the Company’s issuer sponsored subregister and are to have a holding lock applied for the duration of the escrow period applicable to those securities;
- (c) the Company will refuse to acknowledge any disposal (including, without limitation, to register any transfer) of restricted securities during the escrow period applicable to those securities except as permitted by the Listing Rules or ASX;
- (d) a holder of restricted securities will not be entitled to participate in any return of capital on those securities during the escrow period applicable to those securities except as permitted by the Listing Rules or ASX;
- (e) if a holder of restricted securities breaches a restriction deed or a provision of the Company’s constitution restricting a disposal of those securities, the holder will not be entitled to any dividend or distribution, or to exercise any voting rights, in respect of those securities for so long as the breach continues; and
- (f) in this Article 94, and for the purposes of this Constitution generally when used in connection with this Article 94 or its subject matter, the following words and phrases have the meaning given to them in the Listing Rules: “class”; “dispose” or “disposal” (which include using an asset as collateral - see chapter 19 of the Listing Rules); “holding lock”; “issuer sponsored subregister”; “restriction deed”; and “securities”.

Clarifying amendments

- Amend the reference to “twenty-one (21)” in Articles 32(1) and 32(2) to “twenty-eight (28)”.
- Amend the reference to “Article 76(7)” in Article 59(1) to “Article 76(6)”.

If you are attending the virtual Meeting
please retain this Proxy Voting Form
for online Securityholder registration.

[EntityRegistrationDetailsLine1Envelope]
[EntityRegistrationDetailsLine2Envelope]
[EntityRegistrationDetailsLine3Envelope]
[EntityRegistrationDetailsLine4Envelope]
[EntityRegistrationDetailsLine5Envelope]
[EntityRegistrationDetailsLine6Envelope]

[HolderNumber]

Holder Number:
[HolderNumber]

Your proxy voting instruction must be received by **11.00am (MELBOURNE TIME) on Tuesday, 24 November 2020**, being not later than **48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS

The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: <https://investor.automic.com.au/#/home> Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 – APPOINT A PROXY

If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of KMP.

STEP 2 - VOTES ON ITEMS OF BUSINESS

You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item you vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY

You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS

Individual: Where the holding is in one name, the Shareholder must sign.

Joint holding: Where the holding is in more than one name, all Shareholders should sign.

Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.

Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.

Email Address: Please provide your email address in the space provided.

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at <https://automic.com.au>.

Lodging your Proxy Voting Form:

Online:

Use your computer or smartphone to appoint a proxy at

<https://investor.automic.com.au/#/login>

or scan the QR code below using your smartphone

Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.



BY MAIL:

Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:

meetings@automicgroup.com.au

BY FACSIMILE:

+61 2 8583 3040

All enquiries to Automic:

WEBCHAT: <https://automicgroup.com.au/>

PHONE: 1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

